Tag: FierceBiotech

Posted on

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown – FierceBiotech


Reuters UK

AstraZeneca squares off against Roche in blockbuster PhIII asthma showdown
FierceBiotech
Receptos, meanwhile, in-licensed an IL-13 drug from AbbVie after the pharma company decided to de-prioritize its respiratory efforts, including a program for asthma. Receptos is testing RPC4046 for Eosinophilic esophagitis, an orphan disease, and …
AstraZeneca starts final-stage tests on severe asthma drugReuters
AstraZeneca share price: Drugmaker starts late-stage asthma drug trialiNVEZZ
AZ severe asthma drug tralokinumab goes into Phase IIIPharmaTimes
IFA Magazine
all 15 news articles »

View full post on asthma – Google News

Posted on

Cytos hits the self-destruct button as PhIIb asthma study bombs – FierceBiotech

Cytos hits the self-destruct button as PhIIb asthma study bombs
FierceBiotech
The Swiss biotech said that its asthma drug CYT003 flunked its primary as well as secondary endpoints in the critically important study, making it all but impossible to raise more funds for the company. As a result, CEO Christian Itin has hit the self …
Cytos Begins Layoff Process, Eyes Liquidation After Phase IIb FailureGenetic Engineering News
Cytos considering options to wind down companyReuters

all 5 news articles »

View full post on asthma – Google News

Posted on

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes – FierceBiotech


Drug Discovery & Development

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes
FierceBiotech
Roche's ($RHHBY) lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment. The drug …
Biologic May Tame Severe AsthmaMedPage Today
Roche drug cuts asthma attacks, improves lung function -studyReuters
Lebrikizumab Phase 2b Data Show Reduction of Asthma Attack RatesDrug Discovery & Development
PharmaTimes
all 12 news articles »

View full post on asthma – Google News

Posted on

KaloBios calls it quits on its asthma drug after a Phase II flop – FierceBiotech

KaloBios calls it quits on its asthma drug after a Phase II flop
FierceBiotech
San Francisco's KaloBios ($KBIO) is hitting the breaks on one of its lead programs after the asthma treatment missed its primary endpoint in a mid-stage trial, sending the company's shares into a 30% tailspin. The drug, KB003, failed to significantly …
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios stock slides; to stop asthma studyMarketWatch
KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma StudyRTT News
San Francisco Business Times (blog)
all 29 news articles »

View full post on asthma – Google News

Posted on

Array BioPharma scores midstage success for asthma drug – FierceBiotech

Array BioPharma scores midstage success for asthma drug
FierceBiotech
Array BioPharma has another asset on deck for a potential partnership. The Boulder, CO-based drug developer has touted upbeat Phase II data for an experimental drug in patients with allergic asthma, and the company ($ARRY) plans to seek a partner to …
Array asthma drug meets main goal in mid-stage studyReuters
Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung …Wall Street Journal
Array Seeks Asthma Drug Partner Following Mid-Stage Study ResultsTheStreet.com
RTT News –Benzinga –Yahoo! News
all 8 news articles »

View full post on asthma – Google News

Posted on

Cytos Biotechnology soars on results of asthma-drug study – FierceBiotech

Cytos Biotechnology soars on results of asthma-drug study
FierceBiotech
After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning …
Cytos Rises After Asthma Drug Succeeds in Trial: Zurich MoverBloomberg
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study …PR Newswire (press release)

all 3 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca and Rigel strike asthma deal worth up to $100M – FierceBiotech

AstraZeneca and Rigel strike asthma deal worth up to $100M
FierceBiotech
The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma.
AstraZeneca And Rigel Sign Worldwide License Agreement For A …MarketWatch (press release)
AstraZeneca, Rigel to Develop Asthma TreatmentNASDAQ
Rigel, AstraZeneca strike potential $100M asthma drug dealBizjournals.com (blog)

all 19 news articles »

View full post on asthma – Google News

Posted on

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma … – FierceBiotech

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
FierceBiotech
MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in …
MediciNova Reports Results Of A Phase 2b Trial Of MN-221 In Asthma ExacerbationsNASDAQ

all 28 news articles »

View full post on asthma – Google News